SecBot SecBot
8-K ·Filed Nov 3, 2026

IDYA

IDEAYA Biosciences, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed13d 16h ago SEC0001193125-26-444225
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The NDA submission for darovasertib is the key near-term catalyst; FDA review under RTOR could yield a decision in H1 2027. The OptimUM-010 closure removes a cash drain and signals capital reallocation toward IDE849 and IDE892 registrational trials. Watch for initial IDE849 Phase 1/2 data by end of 2026 or early 2027 and the R&D Day on November 16 for preclinical MTAP/KRAS data.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$31.33
T+0 close · Nov 3, 2026 · via day close
Latest settled
+1.34%
T+5 · $31.75 · next T+20 in 15d
Vs SPY
+1.93%
α at T+5
Latest observation
+2.26%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $31.33entry
  2. T+1 · 13d ago +3.29%α +1.64% · $32.36
  3. T+5 · 7d ago +1.34%α +1.93% · $31.75
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The company completed its NDA submission for darovasertib in metastatic uveal melanoma and announced the closure of the Phase 3 OptimUM-010 trial, expected to save $100-125M for reallocation to other pipeline programs. Cash stood at $1.15B with runway into 2030 unchanged.

Key Financial Metrics

Revenue
$10.2M
est $7.6M · +34.8%

Key Facts

  • Collaboration revenue of $10.2M for Q3 2026, up from $8.9M in Q2 2026
  • Cash, cash equivalents and marketable securities of $1.15B as of September 30, 2026
  • NDA submitted to FDA for darovasertib plus crizotinib in metastatic uveal melanoma under RTOR program
  • Phase 3 OptimUM-010 trial closed due to enrollment challenges, expected cost savings of $100-125M
  • Plans to initiate two Phase 3 registrational trials for IDE849 in ES-SCLC and NEC by year end
  • R&D expenses of $121.6M for Q3 2026, up from $108.7M in Q2 2026
  • G&A expenses of $26.3M for Q3 2026, up from $22.5M in Q2 2026
  • Cash runway guidance into 2030 unchanged

Financial Impact

Net loss widened to $125.7M in Q3 2026 from $112.5M in Q2 2026; cash burn of ~$90M from $1.24B to $1.15B; $100-125M in cost savings from trial closure to be reallocated

revenuenet losscashoperating expenses

Risk Factors

  • FDA may not approve darovasertib NDA or may require additional data
  • IDE849 Phase 3 trials may face enrollment or efficacy challenges
  • Cash burn rate is increasing with R&D and G&A expenses rising quarter-over-quarter
  • Competition from other DLL3-targeted therapies (e.g., tarlatamab) could limit IDE849's market opportunity
  • OptimUM-010 closure may signal broader enrollment difficulties across the pipeline

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-444225
Document: idya-20261103.htm0001193125-26-444225
Document: 0001193125-26-444225-index-headers.html0001193125-26-444225
Document: 0001193125-26-444225-index.html0001193125-26-444225
Document: 0001193125-26-444225.txt0001193125-26-444225
8-K Data (Synthetic)0001193125-26-444225

Track record

13 reports on IDYA

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
  2. Nov 3, 202613d ago 8-K Neutral 5/10 Viewing Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
  3. Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
  4. Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
  5. Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
  6. Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
  7. Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
  8. Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
  9. Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
  10. May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 8h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026